Please login to the form below

hyperkalaemia

This page shows the latest hyperkalaemia news and features for those working in and with pharma, biotech and healthcare.

NICE says no to AZ and Vifor’s rival hyperkalaemia drugs

Between 1% and 10% of hospital inpatients have hyperkalaemia. Many patients won’t display any symptoms, but some severe cases can lead to cardiac arrest. ... Hyperkalaemia is also seen in patients taking common medications for heart failure, such as

Latest news

AZ gets US approval for Veltassa rival Lokelma

But GlobalData predicts Veltassa has the edge due to positive data in chronic hyperkalaemia. ... AstraZeneca has picked up FDA approval for its hyperkalaemia treatment Lokelma, allowing it to compete head-to-head with rival Vifor Pharma on both sides of
Daily Brief: AI to boost early NHS cancer diagnosis, AZ shareholder revolt, Juluca approval

The company has a number of promising new cancer treatments, and has just received FDA approval for the delayed hyperkalaemia drug Lokelma.
AZ finally gets EU nod for Veltassa rival Lokelma

And expects a US FDA verdict for the hyperkalaemia treatment later this year. ... The approval of Lokelma “addresses a significant unmet need by bringing a rapid and sustained therapeutic option for patients with hyperkalaemia,” she added.
Vifor wins European approval for Veltassa

European Commission approves the drug to treat hyperkalaemia. The European Commission (EC) has approved Vifor’s Veltassa (patiromer) to treat adults with hyperkalaemia, a potentially life threatening condition which can cause ... The European
FDA turns down AZ's ZS-9 once again on manufacturing issues

The US regulator issued a Complete Response Letter to ZS Pharma regarding its application for ZS-9 (sodium zirconium cyclosilicate) as a treatment for the condition - known as hyperkalaemia - after an ... Veltassa was launched in early 2016 - becoming

More from news
Approximately 5 fully matching, plus 8 partially matching documents found.

Latest Intelligence

Deal Watch July 2016

for the treatment of hyperkalaemia.
Deal Watch November 2015

Paying $90 per share (headline value $2.7bn) in acquiring ZS Pharma, AstraZeneca gains access to ZS-9, a possible best in class product for hyperkalaemia which is under FDA review. ... ZS Pharma. AstraZeneca. Acquisition - company. Lead product ZS-9,
Pharma deals during October 2013

Examples of recent IPOS. Company. Product/technology. Target ($m). Relypsa. Patiromer for hyperkalaemia in chronic kidney disease (phase III).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

AD – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Digital Account Director: Salary TBC

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

PR Director – Health & Wellbeing – Mat Cover (4 days a week)...: Salary TBC

Senior Medical Writer: Up to £50, 000 with Benefits

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior Medical Writer: Great salary and benefits

Account Director, Medical Education: Salary TBC

Senior Planner – Healthcare Advertising – New Role: Salary TBC

Senior Medical Writer: Salary TBC

Project/ Events Manager – Medical Education and Events Agency: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Account/ Project Director – Medical Affairs – Surrey: Salary TBC

Project Manager/ Account Manager: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

The importance of co-creation with patients: Overcoming the barriers...
Three billboards on the road to multichannel: Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence: Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....